# MaveriX Oncology, Inc.

> MaveriX Oncology is a Palo Alto biotech developing conditionally activated small molecule drug conjugates (CA-SMDCs) that exploit tumor-associated hydroxylase biology to deliver cytotoxic and immunomodulatory payloads selectively to solid tumors. Its IMPACT-2X platform aims to widen the therapeutic window of chemotherapy and immunotherapy, killing cancer cells while turning 'cold' immunosuppressive tumors 'hot.' Founded by veteran oncology drug developers and backed by PPF Group and SOTIO, the company's lead program is MVX-5005.

- **Founded:** 2014
- **Headquarters:** Palo Alto, California, United States
- **Founders:** Steven A. Everett (Co-Founder & CEO), Rick Panicucci (Co-Founder & Chief Development Officer), Craig Coburn (Co-Founder & SVP Discovery Chemistry)
- **Team size:** Small (roughly 3-10 employees per public data)
- **Products:** IMPACT-2X / CA-SMDC platform, MVX-5005, TTADCs (Targeted-Targeted ADCs)
- **Notable:** Raised $6.5M Series A from PPF Group and SOTIO (2019), Secured a co-development/licensing deal for MVX-5005 with up to $138M in potential milestone payments, Built the CA-SMDC / IMPACT-2X platform exploiting tumor hydroxylase biology

## Products & services

- **IMPACT-2X / CA-SMDC platform** — A platform of conditionally activated small molecule drug conjugates that remain inactive until tumor-associated hydroxylases in the tumor immune microenvironment cleave a masking group, releasing active cytotoxic and immunomodulatory payloads selectively at the tumor.
- **MVX-5005** — The company's lead drug program, for which SOTIO obtained an option to license and co-develop in Europe.
- **TTADCs (Targeted-Targeted ADCs)** — A next-generation antibody-drug conjugate approach combining MaveriX's proprietary therapeutics with validated payloads for an improved safety profile.

## Achievements

- Raised $6.5M Series A from PPF Group and SOTIO (2019)
- Secured a co-development/licensing deal for MVX-5005 with up to $138M in potential milestone payments
- Built the CA-SMDC / IMPACT-2X platform exploiting tumor hydroxylase biology
- Assembled a clinical advisory board including David S. Hong (MD Anderson) and Daniel D. Von Hoff (TGen)

## Latest updates

- **2019-10** — PPF Group and SOTIO invest $6.5M in MaveriX Oncology and its lead program MVX-5005; SOTIO gains a European co-development option.
- **2022-01** — MaveriX featured in Nature on co-targeting cancer and the tumor immune microenvironment with conditionally activated small molecule therapeutics.

## Links

- Website: https://maverixoncology.com
- LinkedIn: https://www.linkedin.com/company/maverix-oncology-inc
- Twitter/X: https://twitter.com/MaveriX_Onc_

---

Profile page: https://yespress.io/maverix-oncology-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13